The effect of thalidomide on experimental autoimmune myasthenia gravis.

[1]  W. Lenz,et al.  Die Thalidomid-Embryopathie* , 1962 .

[2]  G. Mellin,et al.  The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. , 1962, The New England journal of medicine.

[3]  J SHESKIN,et al.  Thalidomide in the treatment of lepra reactions , 1965, Clinical pharmacology and therapeutics.

[4]  J. P. Gusdon,et al.  Effect of thalidomide on the antibody response. , 1968, American journal of obstetrics and gynecology.

[5]  M. Rittenberg,et al.  Antitrinitrophenyl (TNP) Plaque Assay. Primary Response of Balb/c Mice to Soluble and Particulate Immunogen 1 , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[6]  A. Eldefrawi,et al.  Purification and molecular properties of the acetylcholine receptor from Torpedo electroplax. , 1973, Archives of biochemistry and biophysics.

[7]  F. Londoño.  THALIDOMIDE IN THE TREATMENT OF ACTINIC PRURIGO , 1973, International journal of dermatology.

[8]  R. Almon,et al.  Acetylcholine receptor antibodies in myasthenia gravis. , 1975, The New England journal of medicine.

[9]  J. Lindstrom,et al.  EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS: CELLULAR AND HUMORAL IMMUNE RESPONSES * , 1976, Annals of the New York Academy of Sciences.

[10]  Drachman Db.  Myasthenia gravis (second of two parts). , 1978 .

[11]  M. Lecha,et al.  Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. , 1979, Archives of dermatology.

[12]  K. Ricker,et al.  EFFECT OF IMMUNOSUPPRESSIVE DRUGS (AZATHIOPRINE) , 1981, Annals of the New York Academy of Sciences.

[13]  R. Miranda,et al.  Inhibition of de Novo IgM Antibody Synthesis by Thalidomide as a Relevant Mechanism of Action in Leprosy , 1981, Scandinavian journal of immunology.

[14]  D. Drachman.  The biology of myasthenia gravis. , 1981, Annual review of neuroscience.

[15]  R. Deitch.  After the Trial at Leicester , 1981, The Lancet.

[16]  R. Barnhill,et al.  Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. , 1982, Journal of the American Academy of Dermatology.

[17]  A. Pestronk,et al.  Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide , 1982, Muscle & nerve.

[18]  J P Changeux,et al.  Acetylcholine receptor: an allosteric protein. , 1984, Science.

[19]  E. Grosshans,et al.  Thalidomide Therapy for Inflammatory Dermatoses , 1984, International journal of dermatology.

[20]  H. Coslett,et al.  Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 Patients , 1984, Annals of neurology.

[21]  H. Koch.  Thalidomide and congeners as anti-inflammatory agents. , 1985, Progress in medicinal chemistry.

[22]  A. Pestronk,et al.  Treatment of experimental myasthenia gravis with cyclosporin A. , 1985, Clinical immunology and immunopathology.

[23]  E. Shannon,et al.  Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. , 1985, Leprosy review.

[24]  G. Gordon,et al.  Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. , 1986, Transplantation.

[25]  S. Heinemann,et al.  Molecular Biology of Nicotinic Acetylcholine Receptors , 1987, Annals of the New York Academy of Sciences.

[26]  D. Drachman.  Present and future treatment of myasthenia gravis. , 1987, The New England journal of medicine.

[27]  A. Vora,et al.  SUCCESSFUL TREATMENT WITH THALIDOMIDE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION , 1988, The Lancet.

[28]  D. Noe,et al.  Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. , 1989, Drug metabolism and disposition: the biological fate of chemicals.